Articles by Disease (Dyskinesias)

Pre-clinical Aspects and Contemporary Treatments of Parkinson’s Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 23
Page: 996-1014
Author(s): Partosh Chhabra, Rishabh, Shivani Singla, Sunayna Choudhary, Shivam Kohli, Nitin Bansal and Seema Bansal*

An Update on Parkinson’s Disease and its Neurodegenerative Counterparts

Journal: Current Medicinal Chemistry
Volume: 31
Page: 2770-2787
Author(s): Hussaini Adam, Subash C.B. Gopinath*, M.K. Md Arshad, Tijjani Adam, Sreeramanan Subramaniam and Uda Hashim

Neuronal Vulnerability to Degeneration in Parkinson’s Disease and Therapeutic Approaches

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 23
Page: 715-730
Author(s): Tanushree Sharma, Rajnish Kumar and Sayali Mukherjee*

Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease

Journal: Central Nervous System Agents in Medicinal Chemistry
Volume: 24
Page: 22-44
Author(s): Priya P. Shejul and Gaurav M. Doshi*

Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies

Journal: Current Medicinal Chemistry
Volume: 31
Page: 1485-1511
Author(s): Konstantin Yenkoyan*, Zadik Ounanian, Margarita Mirumyan, Liana Hayrapetyan, Naira Zakaryan, Raisa Sahakyan and Geir Bjørklund*

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease

Journal: CNS & Neurological Disorders - Drug Targets
Volume: 23
Page: 476-487
Author(s): Erwan Bezard, David Gray, Rouba Kozak, Matthew Leoni, Cari Combs and Sridhar Duvvuri*

Articles by Disease (Dyskinesias)

Pre-clinical Aspects and Contemporary Treatments of Parkinson’s Disease

An Update on Parkinson’s Disease and its Neurodegenerative Counterparts

Neuronal Vulnerability to Degeneration in Parkinson’s Disease and Therapeutic Approaches

Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease

Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease

Why do some Children Get Sick with Recurrent Respiratory Infections?

NLS-3 (Levophacetoperane or (R,R) Phacetoperane): A Reverse Ester of Methylphenidate: A Literature Review

Paraquat and Parkinson’s Disease: The Molecular Crosstalk of Upstream Signal Transduction Pathways Leading to Apoptosis

Primary Ciliary Dyskinesia - An Update on the Genetics of Underlying Pathological Mechanisms